Key result
Gene-silencing therapies lower lipoprotein(a) up to ~98% in cardiovascular disease, with outcome trials ongoing.
Why the study?
Elevated lipoprotein levels are causally associated with atherosclerotic cardiovascular disease and calcific aortic stenosis, yet measurement remains absent from most routine cardiovascular screening strategies and conventional therapies such as statins exert minimal or no effect.
Do gene-silencing therapies (antisense oligonucleotides and siRNAs) effectively reduce lipoprotein(a) levels and cardiovascular events in patients with elevated lipoprotein(a) and cardiovascular disease?
Do gene-silencing therapies (antisense oligonucleotides and siRNAs) effectively reduce lipoprotein(a) levels and cardiovascular events in patients with elevated lipoprotein(a) and cardiovascular disease?
Gene-silencing therapies using ASOs and siRNAs achieve unprecedented 80-98% reductions in genetically determined Lp(a) levels, transforming a historically neglected cardiovascular risk factor into an actionable therapeutic target awaiting definitive phase 3 outcome confirmation.
Answers are grounded in this paper and cite their sources.
Lp(a) remains neglected in routine screening; leaves open whether its measurement improves risk stratification in ASCVD.
Lipoprotein is a lipid particle of predominantly genetic origin whose elevated plasma levels are causally and independently associated with the risk of atherosclerotic cardiovascular disease and calcific aortic stenosis. Despite its significant population prevalence an estimated 20% of individuals carry risk-associated concentrations Lp measurement remains absent from most routine cardiovascular screening strategies, constituting a neglected risk factor in clinical practice. This article reviews the pathophysiology of Lp, its genetic determination by the LPA locus, the epidemiological and genetic evidence supporting a causal relationship with cardiovascular outcomes, and the emerging therapeutic landscape. Traditionally, available pharmacological interventions such as statins exert minimal or no effect on Lp. However, the advent of gene-silencing therapies based on antisense oligonucleotides and small interfering RNA represents a paradigm shift. The phase 2 Lp(a)HORIZON trial demonstrated that olpasiran, an ASO targeting apo mRNA, produced dose dependent reductions of up to 80% in Lp levels in patients with established cardiovascular disease, with an acceptable safety profile (Tsimikas et al., 2020). Equally promising results have been observed with the siRNA olpasiran and second-generation compounds. This article argues that recognizing Lp as a legitimate therapeutic target requires a revision of screening guidelines and preparation of clinical practice for the imminent incorporation of these therapies. It is concluded that gene silencing of Lp constitutes the most promising frontier of personalized preventive cardiology, and that the Lp HORIZON result marks the inflection point between historical neglect and causal intervention.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2026) conducted a review in Elevated lipoprotein(a) and atherosclerotic cardiovascular disease or calcific aortic stenosis. Gene-silencing therapies targeting LPA mRNA (antisense oligonucleotides such as pelacarsen and siRNAs such as olpasiran and zerlasiran) vs. Placebo or conventional lipid-lowering therapies (statins, niacin) was evaluated on Percentage reduction in plasma lipoprotein(a) levels and major adverse cardiovascular events. Gene-silencing therapies using ASOs and siRNAs reduce plasma lipoprotein(a) levels by 80% to 98% in patients with cardiovascular disease, though phase 3 trials are needed to confirm event reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: